All
- All
- Articles
- Calendar
- Compliance
- Newsletter
- Position Statements
- Press Release
- Regulatory
- Uncategorized
New FDA Draft Guidance on Responding to 483 Observations; What Drug Manufacturers Need to Know Now
By Eric L. Foxman, Pharm. (Ret.) In March 2026, FDA released a significant draft guidance which presents consolidated and formalized expectations for drug manufacturers responses...
Stability Testing
By Mark Land, M.S., RAC-US, AAHP President When I think back to my early days in homeopathy, I recall that in the manufacturing facility there was...
Branding Part II: How to Create a Motivating, Sustainable Brand Positioning / Strategy
By Cynthia Batterman This article originally appeared in the October 2011 hardcopy-only edition of the AAHP Network News. Building upon a previous article on the...
Branding Part I: A Positioning Statement Is Mission Critical to Your Business
By Cynthia Batterman This article originally appeared in the August 2011 hardcopy-only edition of the AAHP Network News. One of the most important strategic projects that any company can pursue...
Using AI-Powered Sentiment Analysis to Strengthen Marketing and Differentiation in Homeopathic Products
By Brenda van Goethem, Director of Regulatory Compliance and Change Management at Nature's Way Brands, LLC (Schwabe North America) and AAHP Board of Director Artificial...
Marketing of Homeopathic Drug Products: OTC vs. Rx-only
By Eric L. Foxman, Pharm. (Ret.) On a single day in mid-November, FDA issued five warning letters* to a like number of distributors / manufacturers of homeopathic drug...
Honor The Basics
By Mark Land, M.S., RAC-US, AAHP President In this issue, we examine marketing of homeopathic drug products. As I read through the articles, what consistently came to mind was that the...
